Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Sarcoma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × ceritinib × 1 year × Clear all
NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02393625 2026-04-02

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Novartis

Phase 1 Active not recruiting
57 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

Novartis

No longer available
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡